Antiglycative Effects of Protocatechuic Acid in the Kidneys of Diabetic Mice

Protocatechuic acid (PCA) at 2 or 4% was supplied to diabetic mice for 12 weeks. PCA treatments increased its deposit in organs and significantly reduced the plasma HbA1c level, the urinary glycative albumin level, and renal production of carboxymethyllysine (CML), pentosidine, sorbitol, and fructos...

Full description

Saved in:
Bibliographic Details
Published in:Journal of agricultural and food chemistry 2011-05, Vol.59 (9), p.5117-5124
Main Authors: Lin, Chia-Yu, Tsai, Shih-Jei, Huang, Chin-Shiu, Yin, Mei-Chin
Format: Article
Language:English
Subjects:
Animals
Biological and medical sciences
Diabetic Nephropathies - drug therapy
Diabetic Nephropathies - metabolism
Food industries
Fundamental and applied biological sciences. Psychology
Glycation End Products, Advanced - metabolism
Glycosylation - drug effects
Humans
Hydroxybenzoates - administration & dosage
Hydroxybenzoates - metabolism
Kidney - drug effects
Kidney - metabolism
Male
Mice
Mice, Inbred BALB C
Molecular Nutrition
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Protocatechuic acid (PCA) at 2 or 4% was supplied to diabetic mice for 12 weeks. PCA treatments increased its deposit in organs and significantly reduced the plasma HbA1c level, the urinary glycative albumin level, and renal production of carboxymethyllysine (CML), pentosidine, sorbitol, and fructose (p < 0.05). However, PCA treatments only at 4% significantly decreased brain content of CML, pentosidine, fructose, and sorbitol (p < 0.05). PCA treatments at 2 and 4% significantly lowered renal activity and mRNA expression of aldose reductase and sorbitol dehydrogenase (p < 0.05), and PCA treatments only at 4% significantly enhanced renal glyoxalase I mRNA expression (p < 0.05). PCA treatments also dose-dependently decreased the renal level of type-IV collagen, fibronectin, and transforming growth factor-β1 (p < 0.05), as well as dose-dependently diminished renal protein kinase C (PKC) activity (p < 0.05); however, PCA treatments only at 4% suppressed renal mRNA expression of PKC-α and PKC-beta (p < 0.05). PCA treatments at 4% significantly restored renal mRNA expression of peroxisome proliferator-activated receptor (PPAR)-α and PPAR-γ, as well as suppressed expression of the advanced glycation end-product receptor (p < 0.05). These findings suggest that the supplement of PCA might be helpful for the prevention or alleviation of glycation-associated diabetic complications.
ISSN:0021-8561
1520-5118
DOI:10.1021/jf200103f